Video

Dr. Tam on Results of the CAPTIVATE Trial in CLL

Author(s):

Constantine S. Tam, MD, MBBS
Conference|ASH Annual Meeting and Exposition

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the results of the phase II CAPTIVATE study in chronic lymphocytic leukemia (CLL).

<<< View more from the 2019 ASH Annual Meeting

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
David C. Fisher, MD
David C. Fisher, MD
Nitin Jain, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Kathleen A. Dorritie, MD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Related Content
DK210 (EGFR) in Advanced Solid Tumors
November 7th 2024

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Radiomic Biomarkers in Uveal Melanoma Metastases | Image Credit: © ReisMedia - stock.adobe.com
November 7th 2024

Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Matthew Cortese, MD, MPH, assistant professor, oncology, Department of Medicine-Lymphoma, Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center
November 6th 2024

Obinutuzumab and Liso-Cel Revisions to CLL/SLL NCCN Guidelines Mark Most Notable Changes of 2024

HD-CAR-1 in Heavily Pretreated CLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 4th 2024

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL